Antibodies to the c3d fragment of complement component 3

一种抗体、补体的技术，应用在抗体、补体蛋白、抗体模拟物/支架等方向

Inactive Publication Date: 2013-08-14
UNIV OF COLORADO THE REGENTS OF
View PDF127 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether complement activation is essential in the pathogenesis and injury of all diseases in which local tissue C3 activation and inflammatory injury occur is uncertain; however, C3 fragment immobilization is almost universally found as a related event

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies to the c3d fragment of complement component 3
  • Antibodies to the c3d fragment of complement component 3
  • Antibodies to the c3d fragment of complement component 3

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0350] Anti-C3d antibody:

[0351] Recombinant human C3d was produced in E. coli using the pGEX expression system as described in Hannan, J.P., et al. (2005) J. Mol. Biol. 346, 845-858. Briefly, ampicillin-resistant clones were used to initiate overnight cultures, and cultures were expanded to 1 L and grown at 37°C until reaching A 600 =0.3. Cultures were induced with 0.3 mM isopropyl-β-D-thiogalactoside overnight at 30°C and then harvested by centrifugation. The harvested bacterial pellet was resuspended in glutathione-s-transferase column buffer (50 mM Tris-HCl, pH 8.0, 250 mM NaCl, 1 mM EDTA) and lysed by sonication. Lysates were clarified by centrifugation and applied to GStrap columns (GE Biosciences). C3d was cleaved from the column by digestion with 50 units of thrombin overnight at 4°C, followed by purification by size exclusion chromatography. The purity of C3d was monitored by SDS-PAGE.

[0352] C3 was immunized with 60 μg of recombinant C3d emulsified in Freund...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin / mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and / or lower effective maintenance doses, and / or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

Description

[0001] related application [0002] This application claims priority to US Provisional Patent Application Serial No. 61 / 357,499, filed June 22, 2010, the disclosure of which is incorporated herein by reference in its entirety. field of invention [0003] The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the classical complement pathway (CCP), the complement lectin / mannose pathway (CMP), or combinations thereof, as well as for the use of diagnostic, prophylactic and Methods and materials for targeting therapeutic agents to localized regions of tissue in the body so that the diagnostic, prophylactic, and therapeutic agents can act more directly on intended target cells or tissues as if administered in a non-targeted, systemic manner or similar agents, have reduced associated systemic effects. Thus, the methods and materials of the invention can achieve increased efficacy, lower threshold effective doses and / or lower ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/28
CPCA61K39/395C07K16/18C07K2317/33C07K2319/00C07K2317/92C07K16/28C07K14/472C07K2317/76A61P1/04A61P1/16A61P1/18A61P11/00A61P11/06A61P13/12A61P15/00A61P17/00A61P17/02A61P19/02A61P21/04A61P25/00A61P25/28A61P27/02A61P29/00A61P3/04A61P31/04A61P31/10A61P31/12A61P33/00A61P35/00A61P37/00A61P37/06A61P37/08A61P5/14A61P7/06A61P7/10A61P9/10A61P3/10
Inventor V·迈克尔·霍勒斯乔舒亚·M·瑟曼路德米拉·库里克
Owner UNIV OF COLORADO THE REGENTS OF
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap